Interactions Between Tamoxifen and Antidepressants via Cytochrome P450 2D6
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Women taking tamoxifen for the treatment or prevention of recurrence of breast cancer are likely to take antidepressants either for a psychiatric disorder or for hot flashes. Recent evidence suggested that some antidepressants inhibit the metabolism of tamoxifen to its more active metabolites by the cytochrome P450 2D6 (CYP2D6) enzyme, thereby decreasing the anticancer effect. This article reviews the literature on the interactions between newer antidepressants and tamoxifen via CYP2D6 and offers treatment recommendations. DATA SOURCES: A literature search of clinical and nonclinical studies published prior to September 2008 was conducted on PubMed. We performed 3 different searches combining the terms tamoxifen and SSRIs; tamoxifen and CYP2D6 inhibitors; and antidepressant and breast cancer recurrence. A fourth search with CYP2D6 inhibition and the generic names of individual antidepressants was carried out. STUDY SELECTION: Seven clinical research articles were selected. Nonclinical research articles about antidepressants were included if they mentioned in vitro or in vivo inhibition of CYP2D6. DATA SYNTHESIS: There is consistent evidence that paroxetine and fluoxetine have a large effect on the metabolism of tamoxifen and should not be used. Indirect evidence indicates that bupropion may also have a large effect on the metabolism of tamoxifen. Venlafaxine has little or no effect on the metabolism of tamoxifen and may be considered the safest choice of antidepressants. Desvenlafaxine is not metabolized by the P450 system and may consequently be another option. Mirtazapine has not been extensively studied, but existing research suggests minimal effect on CYP2D6. The remaining commonly prescribed antidepressants have mild to moderate degrees of CYP2D6 inhibition. CONCLUSIONS: Clinicians treating patients with breast cancer should review the prescription profiles of their patients to evaluate the need for treatment modification. There are safe options for the treatment of depression and clinicians and patients should bear in mind the health risks of untreated depressive states.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 440
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Numakawa, T., Richards, M., Nakajima, S., Adachi, N., Furuta, M., Odaka, H., & Kunugi, H. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00136 · Cited by 86
“, fluoxetine, paroxetine, and sertraline) reduce the efficacy of tamoxifen via interaction with cytochrome P450 2D6, an enzyme for tamoxifen metabolism (92, 93), illustrating the challenges associated with treating a patient with MDD and breast cancer.”
BackgroundJohns, C., Seav, S. M., Dominick, S. A., Gorman, J. R., Li, H., Natarajan, L., Mao, J. J., & Irene Su, H. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3765-4 · Cited by 72
“Paroxetine has been shown to have a strong interaction, while venlafaxine and gabapentin are not known to have an interaction with tamoxifen [42].”
BackgroundZahid, J. A., Grummedal, O., Madsen, M. T., & Gögenur, I. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.10.009 · Cited by 48
Metadata
- Authors
- Desmarais, J. E., & Looper, K. J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-12-15
- Volume
- 70
- Issue
- 12
- Pages
- 1688-1697
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2013249805
- Cited by
- 131
- References
- 0
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interactions Between Tamoxifen and Antidepressants via Cytochrome P450 2D6. https://app.cochat.ai/papers/10.4088/jcp.08r04856blu
- The paper
- Desmarais, J. E., & Looper, K. J. (2009). Interactions Between Tamoxifen and Antidepressants via Cytochrome P450 2D6. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.08r04856blu
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.